Reviewing Calithera Biosciences Inc. (CALA)’s and Innoviva Inc. (NASDAQ:INVA)’s results

This is a contrast between Calithera Biosciences Inc. (NASDAQ:CALA) and Innoviva Inc. (NASDAQ:INVA) based on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Calithera Biosciences Inc. 3 -0.03 43.87M -1.72 0.00
Innoviva Inc. 12 0.40 52.93M 3.37 3.52

We can see in table 1 the earnings per share, top-line revenue and valuation of Calithera Biosciences Inc. and Innoviva Inc.


Table 2 represents Calithera Biosciences Inc. (NASDAQ:CALA) and Innoviva Inc. (NASDAQ:INVA)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Calithera Biosciences Inc. 1,286,774,411.17% -50.5% -44.8%
Innoviva Inc. 443,671,416.60% 334.6% 74.3%

Volatility and Risk

Calithera Biosciences Inc. has a 1.84 beta, while its volatility is 84.00% which is more volatile than S&P 500. From a competition point of view, Innoviva Inc. has a 1.5 beta which is 50.00% more volatile compared to S&P 500.


6.8 and 6.8 are the respective Current Ratio and a Quick Ratio of Calithera Biosciences Inc. Its rival Innoviva Inc.’s Current and Quick Ratios are 42.5 and 42.5 respectively. Innoviva Inc. has a better chance of clearing its pay short and long-term debts than Calithera Biosciences Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Calithera Biosciences Inc. and Innoviva Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Calithera Biosciences Inc. 0 0 1 3.00
Innoviva Inc. 0 0 0 0.00

$7 is Calithera Biosciences Inc.’s average price target while its potential upside is 49.25%.

Institutional & Insider Ownership

Institutional investors owned 61.2% of Calithera Biosciences Inc. shares and 80.5% of Innoviva Inc. shares. Calithera Biosciences Inc.’s share owned by insiders are 0.3%. Insiders Competitively, owned 0.2% of Innoviva Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Calithera Biosciences Inc. 0.24% 6.53% -28.5% -2.75% 3.41% 5.74%
Innoviva Inc. -8.83% -18.35% -14.84% -34.8% -15.98% -31.92%

For the past year Calithera Biosciences Inc. has 5.74% stronger performance while Innoviva Inc. has -31.92% weaker performance.


Innoviva Inc. beats Calithera Biosciences Inc. on 8 of the 12 factors.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.